<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2189">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132660</url>
  </required_header>
  <id_info>
    <org_study_id>C3825-R</org_study_id>
    <nct_id>NCT05132660</nct_id>
  </id_info>
  <brief_title>Treating Early Stage Diabetic Retinopathy</brief_title>
  <acronym>TESDR</acronym>
  <official_title>Treating Early Stage Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if levodopa will slow the appearance of blood vessel changes in the eyes of&#xD;
      patients with diabetes. Treatment will be started in patients with diabetes show delays in&#xD;
      the electrical activity of the retina when measured non-invasively with a electroretinogram.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic Retinopathy (DR) is a leading cause of vision loss in the US. To detect DR,&#xD;
      individuals with diabetes are instructed to receive annual eye exams until visible&#xD;
      retinopathy such as hemorrhages or aneurysms appear that often take years to develop. Even&#xD;
      so, treatment is only provided when visually threatening disease is detected. The&#xD;
      investigators' group and others have established that in people with diabetes, retinal&#xD;
      neuronal dysfunction precedes clinically visible retinopathy. Non-invasive recordings of&#xD;
      retinal function using the electroretinogram (ERG) have shown dysfunction with diabetes,&#xD;
      particularly in the oscillatory potentials (OPs) that are generated by inner retinal neurons.&#xD;
      A fundamental gap in the knowledge of DR pathology is whether neuronal dysfunction is&#xD;
      associated with or causal to the late stage vascular defects. The overall hypothesis is that&#xD;
      neuronal defects precede vascular defects in DR and that treating neuronal deficits early in&#xD;
      DR will prevent late stage vascular defects that result in vision loss.&#xD;
&#xD;
      Dopamine, a key neuromodulator in the retina, is reduced in DR. The investigators&#xD;
      demonstrated that treating rodent models of diabetes with levodopa, a dopamine precursor, is&#xD;
      neuroprotective for neuronal dysfunction. Importantly, the investigators also showed that in&#xD;
      patients with diabetes and retinal dysfunction, but without retinopathy, levodopa taken for&#xD;
      only 2 weeks restored retinal dysfunction to normal levels. Thus, the preliminary data&#xD;
      suggest that earlier screening and treatment are possible to prevent or delay retinal&#xD;
      dysfunction in early DR. Since current clinical management of DR is directed at more advanced&#xD;
      stages of disease when vascular defects are present, it is critical to determine if levodopa&#xD;
      will also prevent vascular pathology.&#xD;
&#xD;
      The investigators propose the following specific aims to investigate the link between&#xD;
      neuronal and vascular defects in DR by using neuronal (dim flash ERG) and vascular (fundus&#xD;
      photography and optical coherence tomography angiography) primary outcome measures:&#xD;
&#xD;
      Aim 1: Investigate whether the appearance of early neuronal dysfunction predicts late stage&#xD;
      vascular pathology in diabetes. The investigators propose follow-up testing on a cohort of&#xD;
      participants with diabetes, and normal or delayed OPs, from a prior clinical study to&#xD;
      determine how many develop signs of retinal vascular defects after 3-5 years.&#xD;
&#xD;
      Aim 2: Determine whether levodopa treatment initiated at detection of retinal dysfunction&#xD;
      will prevent retinal dysfunction and vascular defects. The investigators will conduct a&#xD;
      randomized clinical trial with levodopa versus placebo using participants with diabetes and&#xD;
      confirmed OP delays from two groups: 1) without retinopathy and 2) with the earliest signs of&#xD;
      DR (microaneurysms). Patients will receive levodopa or placebo twice daily for 6- or&#xD;
      24-months. For the 6-month duration, testing will be done at baseline, 3 months and 6 months.&#xD;
      Patients will then return to routine standard of care and be re-tested at 12 and 24 months.&#xD;
      For the 24-month duration, testing will be done at baseline and every 3 months until 24&#xD;
      months. Participants will be carefully monitored for levodopa side effects with the&#xD;
      assistance of a neurologist.&#xD;
&#xD;
      Determining the association between neuronal and vascular defects in DR is critical to&#xD;
      shifting clinical practice toward early diagnostic markers, a move that could transform the&#xD;
      way DR is monitored and treated, ultimately leading to better preservation of normal visual&#xD;
      function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2027</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Sinemet CR 25 mg carbidopa/100 mg levodopa or placebo will be given twice daily for 6 months or 24 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participants will be assigned a number and treatment group will be assigned according to randomization strategy by pharmacy personnel</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Electroretinogram</measure>
    <time_frame>24 months</time_frame>
    <description>Electrical activity of the retina measured by non-invasive electrodes on the face to a flash to light. A waveform will be recorded and timing of the waves measured in milliseconds</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography angiography</measure>
    <time_frame>24 months</time_frame>
    <description>Non-invasive imaging of the retina to observe retinal and vascular structure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fundus photographs</measure>
    <time_frame>24 months</time_frame>
    <description>Image of the inside of the eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>24 months</time_frame>
    <description>Blood glucose test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">244</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Sinemet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg carbidopa/100 mg levodopa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill of similar size/shape</description>
  </arm_group>
  <arm_group>
    <arm_group_label>follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Follow-up testing on participants previously prescribed levodopa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sinemet CR</intervention_name>
    <description>25 mg carbidopa/100 mg levodopa</description>
    <arm_group_label>Sinemet</arm_group_label>
    <other_name>Levodopa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo pill of similar size/shape</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HbA1c 8-12%&#xD;
&#xD;
          -  Diabetic patients with no retinopathy as screened with teleretinal imaging&#xD;
&#xD;
          -  Diabetic patients with microaneurysms as detected with fundus teleretinal screening&#xD;
&#xD;
          -  ERG oscillatory potential delays in response to dim flash stimuli&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with pituitary tumor, psychosis, Parkinson's disease&#xD;
&#xD;
          -  Patients with confounding ocular disease (visually significant cataract, glaucoma,&#xD;
             macular degeneration, retinitis pigmentosa)&#xD;
&#xD;
          -  Patients with cognitive deficits (score of 24 or less on the Montreal Cognitive&#xD;
&#xD;
          -  Assessment-MOCA&#xD;
&#xD;
          -  No anti-VEGF or steroid treatments within the last 12 months&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Machelle T. Pardue, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlanta VA Medical and Rehab Center, Decatur, GA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Machelle T Pardue, PhD</last_name>
    <phone>(404) 321-6111</phone>
    <phone_ext>207342</phone_ext>
    <email>Machelle.Pardue@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atlanta VA Medical and Rehab Center, Decatur, GA</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ashley N Scales</last_name>
      <phone>404-321-6111</phone>
      <phone_ext>23952</phone_ext>
      <email>Ashley.Scales@va.gov</email>
    </contact>
    <investigator>
      <last_name>Machelle T. Pardue, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

